United Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1997
Net Income	984.8	727.3	475.8	514.8	-104.5	589.2	417.9	713.7	651.6	340.1	Upgrade
Depreciation & Amortization	53.2	51.3	49.9	49.9	45.9	35.9	31	31.6	32.9	32.2	Upgrade
Share-Based Compensation	39.1	106.8	138.5	163.8	45.4	-26.4	73.5	6.2	242.9	159.3	Upgrade
Other Operating Activities	-99.1	-82.9	-66	27.2	-193.4	179.7	-48.2	-107.9	-544.6	-176.3	Upgrade
Operating Cash Flow	978	802.5	598.2	755.7	-206.6	778.4	474.2	643.6	382.8	355.3	Upgrade
Operating Cash Flow Growth	21.87%	34.15%	-20.84%	-	-	64.15%	-26.32%	68.13%	7.74%	-16.45%	Upgrade
Capital Expenditures	-230.4	-138.8	-120.8	-56.9	-83.7	-184.4	-78	-38	-49.8	-47.4	Upgrade
Acquisitions	-89.2	8.6	0	0	-12.5	-124.1	0.1	-5.2	0	0	Upgrade
Change in Investments	-400	-681.3	-366.1	-681.6	-239.2	-512.1	-757.7	91.5	203.4	385.9	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	350	-	Upgrade
Investing Cash Flow	-719.6	-811.5	-486.9	-738.5	-335.4	-820.6	-835.6	48.3	503.6	338.5	Upgrade
Share Issuance / Repurchase	98	88.4	50	33.8	14	19.5	-206	-488	-351.2	-429.6	Upgrade
Debt Issued / Paid	-102.7	-7.5	0	-51.7	599.3	-13.2	249.3	-15.6	-133.2	-177.8	Upgrade
Other Financing Activities	-7.2	-5.5	-5.2	1	-2.1	-	-	5.9	37.4	30.8	Upgrade
Financing Cash Flow	-11.9	75.4	44.8	-16.9	611.2	6.3	43.3	-497.7	-447	-576.6	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	0.2	-3	-5.3	-3.8	Upgrade
Net Cash Flow	246.5	66.4	156.1	0.3	69.2	-35.9	-317.9	191.2	434.1	113.4	Upgrade
Free Cash Flow	747.6	663.7	477.4	698.8	-290.3	594	396.2	605.6	333	307.9	Upgrade
Free Cash Flow Growth	12.64%	39.02%	-31.68%	-	-	49.92%	-34.58%	81.86%	8.15%	-21.73%	Upgrade
Free Cash Flow Margin	32.12%	34.28%	28.32%	47.11%	-20.04%	36.49%	22.96%	37.88%	22.72%	23.90%	Upgrade
Free Cash Flow Per Share	15.97	14.59	10.63	15.81	-6.63	13.65	9.01	13.83	7.24	6.39	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).